ANI

WNS Announces Fiscal 2024 Fourth Quarter and Full Year Earnings, Provides Guidance for Fiscal 2025

Retrieved on: 
Thursday, April 25, 2024
Accounting, Technology, Professional Services, Outsourcing Business, Business, Marketing, Communications, Data Analytics, Software, Fintech, Human Resources, USD, Business process management, Internet, Investment, AI, Health care, Holding, Webcast, Growth, INR, Public expenditure, ADS, Acquisition, Generative, ANI, GAAP, BPM

WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global digital-led Business Process Management (BPM) solutions, today announced results for the fiscal 2024 fourth quarter and full year ended March 31, 2024.

Key Points: 
  • WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global digital-led Business Process Management (BPM) solutions, today announced results for the fiscal 2024 fourth quarter and full year ended March 31, 2024.
  • Revenue less repair payments* in the fourth quarter was $325.9 million, increasing 6.9% year-over-year and 3.2% sequentially.
  • Excluding exchange rate impacts, constant currency revenue less repair payments* in the fiscal fourth quarter was up 5.9% versus Q4 of last year and 2.4% sequentially.
  • Profit in the fiscal fourth quarter was $12.6 million, as compared to $36.4 million in Q4 of last year and $39.6 million in the previous quarter.

Biopharma Leaders Come Together at Veeva Commercial Summit to Advance Customer-Centric Engagement

Retrieved on: 
Wednesday, April 17, 2024
HCP, Commercial, Software, Environment, Novo Nordisk, Idorsia, Marketing, ANI

PLEASANTON, Calif., April 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Genentech, Novo Nordisk, Takeda, and others will be among the keynote speakers at the 2024 Veeva Commercial Summit, May 7-8 in Boston. Commercial and medical affairs professionals will share how they are innovating across content, data and analytics, and customer interactions to advance the future of customer-centric engagement.

Key Points: 
  • Veeva CEO Peter Gassner will headline the opening keynote, sharing how the recent delivery of Veeva Vault CRM fits into Veeva's commercial vision.
  • "Veeva is committed to commercial execution and bringing life sciences leaders together to share learnings and fresh ideas around commercial strategies and customer engagement to move the industry forward."
  • One of the largest industry events in North America for commercial and medical affairs professionals, Veeva Commercial Summit will host over 1,700 leaders across more than 100 sessions.
  • For more on Veeva Commercial Summit, visit: veeva.com/Summit
    Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

Retrieved on: 
Tuesday, April 9, 2024
IQVIA, ANI, RLD, Pharmaceutical industry

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.

Key Points: 
  • BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.
  • "The launch of Baclofen Oral Suspension represents another entry for ANI into a rapidly growing limited competition market.
  • We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements in a timely manner,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
  • U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

Retrieved on: 
Thursday, April 4, 2024
Sarcoidosis, ANI, Disease, Incidence, Education, Patient, African Americans, Research, FSR, CAC, Inflammation, Human, Granuloma, Pharmaceutical industry

BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.

Key Points: 
  • BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.
  • During the month of April, members of the ANI organization are raising awareness of sarcoidosis by wearing “Say Sarcoidosis” pins offered through FSRs National Awareness Campaign, “Say Sarcoidosis.” In addition, ANI members will also be wearing purple on April 13th in honor of “World Sarcoidosis Awareness Day.”
    According to the FSR, sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas predominately in the lungs and, to a lesser extent, in other organs of the body.
  • “We applaud the Foundation for Sarcoidosis Research’s Awareness Campaign – “Say Sarcoidosis” and their ongoing education and support of people who live with sarcoidosis.
  • “We are grateful for ANI Pharmaceuticals’ commitment to increasing awareness and education about those living with sarcoidosis,” said Mary McGowan, Chief Executive Officer of the FSR.

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

Retrieved on: 
Wednesday, April 3, 2024
Encore Boston Harbor, ANI, Piper Sandler Companies

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.

Key Points: 
  • BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.
  • To schedule a 1x1 meeting with the Company, please email [email protected] .

ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP

Retrieved on: 
Wednesday, March 27, 2024
Health, ANI, Growth, RLD, Patient, Pharmaceutical industry

BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug (RLD) Levaquin®.

Key Points: 
  • BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug (RLD) Levaquin®.
  • The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider.
  • "New product launch execution remains a top priority for ANI as we continue to drive growth in our Generics business.
  • The launch of Levofloxacin Oral Solution reinforces our ability to respond nimbly to market needs as we pursue our purpose of ‘Serving Patients, Improving Lives,’” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.

Adamastor is the premium engineering centre where the first Portuguese supercar is being developed

Retrieved on: 
Wednesday, March 13, 2024
Finite element method, Computational fluid dynamics, Certification, FIA, ANI, Adamastor, Siemens NX, Research, 3D, Wind, Carbon, Formula, CNC, Computer-aided design, SolidWorks, Engineering, CFD, FEA, 3D printing

PORTO, Portugal, March 13, 2024 /PRNewswire/ -- From its facilities in Perafita, on the outskirts of Porto, Adamastor is currently working on the development of the first Portuguese supercar. But the highly specialised team working in the areas of engineering, production and design also has the technical and human resources to design, develop and produce its own tools, equipment and other components, and is also committed to becoming a leader in the execution of engineering projects of excellence at international level, with a special focus on the design of carbon fibre components of the highest quality. Adamastor Advanced Technologies was born.

Key Points: 
  • PORTO, Portugal, March 13, 2024 /PRNewswire/ -- From its facilities in Perafita, on the outskirts of Porto, Adamastor is currently working on the development of the first Portuguese supercar.
  • Although the Portuguese company is fully focused on conquering its space in the exclusive low-volume supercar segment, it also aims to establish itself as a centre of excellence by providing consultancy, design and engineering conception services through Adamastor Advanced Technologies.
  • Adamastor's various in-house technology projects include an innovative suspension system developed entirely in-house, registered and published under an international patent.
  • Adamastor is also proud of the certification awarded by the Agência Nacional de Inovação (ANI) for its suitability to carry out research and development activities.

Adamastor is the premium engineering centre where the first Portuguese supercar is being developed

Retrieved on: 
Wednesday, March 13, 2024
Finite element method, Computational fluid dynamics, Certification, FIA, ANI, Adamastor, Siemens NX, Research, 3D, Wind, Carbon, Formula, CNC, Computer-aided design, SolidWorks, Engineering, CFD, FEA, 3D printing

PORTO, Portugal, March 13, 2024 /PRNewswire/ -- From its facilities in Perafita, on the outskirts of Porto, Adamastor is currently working on the development of the first Portuguese supercar. But the highly specialised team working in the areas of engineering, production and design also has the technical and human resources to design, develop and produce its own tools, equipment and other components, and is also committed to becoming a leader in the execution of engineering projects of excellence at international level, with a special focus on the design of carbon fibre components of the highest quality. Adamastor Advanced Technologies was born.

Key Points: 
  • PORTO, Portugal, March 13, 2024 /PRNewswire/ -- From its facilities in Perafita, on the outskirts of Porto, Adamastor is currently working on the development of the first Portuguese supercar.
  • Although the Portuguese company is fully focused on conquering its space in the exclusive low-volume supercar segment, it also aims to establish itself as a centre of excellence by providing consultancy, design and engineering conception services through Adamastor Advanced Technologies.
  • Adamastor's various in-house technology projects include an innovative suspension system developed entirely in-house, registered and published under an international patent.
  • Adamastor is also proud of the certification awarded by the Agência Nacional de Inovação (ANI) for its suitability to carry out research and development activities.

P10 Reports Fourth Quarter and Full Year 2023 Earnings Results

Retrieved on: 
Thursday, February 29, 2024
EVP, Investment, PX, Growth, Perella Weinberg Partners, ANI, GAAP, Executive, Goldman Sachs, EPS, Guggenheim Partners, Financial institution, Management

DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX) (the “Company”), a leading private markets solutions provider, today reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- P10, Inc. (NYSE: PX) (the “Company”), a leading private markets solutions provider, today reported financial results for the fourth quarter and year ended December 31, 2023.
  • “P10 advanced key operational and investment initiatives in 2023 while generating double-digit asset growth and strong top line growth to close the year,” said Luke Sarsfield, P10 Chief Executive Officer.
  • On February 27, 2024, P10 appointed Arjay Jensen to the newly formed role of EVP, Head of Strategy and M&A.
  • Mr. Jensen has built a distinguished M&A track record and brings extensive transactional, team management and financial markets experience to P10.

ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
Thursday, February 29, 2024
ANI, Marketing, GAAP, Depreciation, Insurance

Beginning in the fourth quarter of 2022, ANI no longer excludes expense for In-Process Research & Development or Cortrophin Gel pre-launch charges and sales and marketing expenses from its non-GAAP results.

Key Points: 
  • Beginning in the fourth quarter of 2022, ANI no longer excludes expense for In-Process Research & Development or Cortrophin Gel pre-launch charges and sales and marketing expenses from its non-GAAP results.
  • Beginning in the fourth quarter of 2022, ANI no longer excludes expense for In-Process Research & Development or Cortrophin Gel pre-launch charges and sales and marketing expenses from its non-GAAP results.
  • A reconciliation of adjusted non-GAAP net income (loss) to the most directly comparable GAAP financial measure is provided below.
  • A reconciliation of adjusted non-GAAP diluted earnings (loss) per share to the most directly comparable GAAP financial measure is provided below.